Publication date: Jul 08, 2025
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinsons disease is complete, three months ahead of the original goal, the therapys developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up to 20 adults, ages 30-85, at several sites in Australia until the end of July. Enrol .. .
| Concepts | Keywords |
|---|---|
| Australia | Activity |
| July | Clinical |
| Parkinsons | Csf |
| Volunteer | Enrollment |
| Enzyme | |
| Gba1 | |
| Gcase | |
| Gt | |
| Months | |
| Mutations | |
| Parkinsons | |
| Participants | |
| Phase | |
| Target | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Tropicamide |
| pathway | REACTOME | Release |
| disease | MESH | disease progression |
| disease | MESH | dyskinesia |
(Visited 4 times, 1 visits today)